The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-founder and managing director Sander Slootweg says there’s still more that can be done to fund future European innovations and improve Europe’s competitiveness globally. “We’ve observed in Europe that although we see great science, and we’ve been able to build great companies, in terms of the absolute magnitude of the ecosystem, we’re still lagging behind the U.S., and also China is coming up quickly,” Slootweg said in conversation with BioCentury's Stephen Hansen.
00:00 - Introduction 01:34 - Forbion’s growth 05:35 - Deal flow in Europe 10:20 - Green Investing 14:24 - Sourcing Asia Deals 22:20 - Unlocking the EU’s Capital 27:54 - Speeding Up Trials 30:13 - Building a Thriving EU Market 34:38 - Central & Eastern Europe
Podden och tillhörande omslagsbild på den här sidan tillhör
BioCentury. Innehållet i podden är skapat av BioCentury och inte av,
eller tillsammans med, Poddtoppen.